Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David Bernasconi

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Genome Research|January 31, 2012
A multiplicity of factors contributes to selective RNA polymerase III occupancy of a subset of RNA polymerase III genes in mouse liverDonatella Canella, David Bernasconi, Federica Gilardi, et al.
Analytical Chemistry|January 9, 2015
Rapid, sensitive and real-time multiplexing platform for the analysis of protein and nucleic-acid biomarkersDidier Falconnet, Joseph She, Raphaël Tornay, et al.
Genome Research|April 9, 2014
Quantifying ChIP-seq data: a spiking method providing an internal reference for sample-to-sample normalizationNicolas Bonhoure, Gergana Bounova, David Bernasconi, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance StudyAntonella Poloni, Klas Raaschou-Jensen, Francisca Hernandez Mohedo, et al.
Annali Italiani Di Chirurgia|April 16, 2026
Multistage Management of Splenic Flexure Adenocarcinoma in Suspected <i>MUTYH</i>-Associated Polyposis: A Case ReportAndrea Costanzi, Humberto Tapia Gomez, Giulia Schievano, et al.
Nanoscale|December 5, 2019
Strong second-harmonic generation from Au-Al heterodimersJiyong Wang, Jérémy Butet, Gabriel David Bernasconi, et al.
Transplantation and Cellular Therapy|November 14, 2025
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World SettingBradley D Hunter, Matthew Lunning, Mazyar Shadman, et al.
Blood|March 3, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomaJennifer L Crombie, Sairah Ahmed, Matthew J Frigault, et al.
The Lancet. Oncology|July 13, 2010
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisWendy De Roock, Bart Claes, David Bernasconi, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Genome Research|January 31, 2012
A multiplicity of factors contributes to selective RNA polymerase III occupancy of a subset of RNA polymerase III genes in mouse liverDonatella Canella, David Bernasconi, Federica Gilardi, et al.
Analytical Chemistry|January 9, 2015
Rapid, sensitive and real-time multiplexing platform for the analysis of protein and nucleic-acid biomarkersDidier Falconnet, Joseph She, Raphaël Tornay, et al.
Genome Research|April 9, 2014
Quantifying ChIP-seq data: a spiking method providing an internal reference for sample-to-sample normalizationNicolas Bonhoure, Gergana Bounova, David Bernasconi, et al.
Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
Lenalidomide in Transfusion-Dependent IPSS Low- or Intermediate-1-Risk Myelodysplastic Syndromes and Isolated Del(5q): Results of a European Postauthorization Safety Surveillance StudyAntonella Poloni, Klas Raaschou-Jensen, Francisca Hernandez Mohedo, et al.
Annali Italiani Di Chirurgia|April 16, 2026
Multistage Management of Splenic Flexure Adenocarcinoma in Suspected <i>MUTYH</i>-Associated Polyposis: A Case ReportAndrea Costanzi, Humberto Tapia Gomez, Giulia Schievano, et al.
Nanoscale|December 5, 2019
Strong second-harmonic generation from Au-Al heterodimersJiyong Wang, Jérémy Butet, Gabriel David Bernasconi, et al.
Transplantation and Cellular Therapy|November 14, 2025
CRS or ICANS Are Rare Beyond 2 Weeks After Lisocabtagene Maraleucel Infusion: Data From Clinical Trials and the Real-World SettingBradley D Hunter, Matthew Lunning, Mazyar Shadman, et al.
Blood|March 3, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphomaJennifer L Crombie, Sairah Ahmed, Matthew J Frigault, et al.
The Lancet. Oncology|July 13, 2010
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysisWendy De Roock, Bart Claes, David Bernasconi, et al.
Pageof 1